Perspectives on the Risk-Stratified Treatment of Multiple Myeloma-Reference-Cited by-同舟云学术

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Published:2022-06-02 Issue:4 Volume:3 Page:273-284
ISSN:2643-3230
Container-title:Blood Cancer Discovery
language:en
Short-container-title:

Author:

Davies Faith E.¹^ORCID,Pawlyn Charlotte²³^ORCID,Usmani Saad Z.⁴,San-Miguel Jesus F.⁵^ORCID,Einsele Hermann⁶,Boyle Eileen M.¹^ORCID,Corre Jill⁷^ORCID,Auclair Daniel⁸,Cho Hearn Jay⁸⁹^ORCID,Lonial Sagar¹⁰,Sonneveld Pieter¹¹,Stewart A. Keith¹²,Bergsagel P. Leif¹³^ORCID,Kaiser Martin F.³¹⁴^ORCID,Weisel Katja¹⁵,Keats Jonathan J.¹⁶^ORCID,Mikhael Joseph R.¹⁷^ORCID,Morgan Kathryn E.¹⁸,Ghobrial Irene M.¹⁹,Orlowski Robert Z.²⁰^ORCID,Landgren C. Ola²¹^ORCID,Gay Francesca²²^ORCID,Caers Joseph²³,Chng Wee Joo²⁴²⁵²⁶^ORCID,Chari Ajai⁹^ORCID,Walker Brian A.²⁴^ORCID,Kumar Shaji K.²⁵^ORCID,Costa Luciano J.²⁶^ORCID,Anderson Kenneth C.¹⁹^ORCID,Morgan Gareth J.¹^ORCID

Affiliation:

1. 1Perlmutter Cancer Center, NYU Langone, New York, New York.

2. 2Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

3. 3The Royal Marsden Hospital, Department of Haematology, London, United Kingdom.

4. 4Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

5. 5Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

6. 6Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

7. 7Unité de Génomique du Myélome, Institut Universitaire du Cancer, Toulouse France. 8Institut National de la Santé et de la Recherche Médicale, Paris, France.

8. 9The Multiple Myeloma Research Foundation, Norwalk, Connecticut.

9. 10Multiple Myeloma Center of Excellence, Icahn School of Medicine at Mt. Sinai, New York, New York.

10. 11Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

11. 12Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, the Netherlands.

12. 13University Health Network and the Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

13. 14Department of Medicine, Mayo Clinic, Arizona.

14. 15Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.

15. 16Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

16. 17Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, Arizona.

17. 18Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona.

18. 19Myeloma Patients Europe, Brussels, Belgium.

19. 20Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

20. 21Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

21. 22Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

22. 23Division of Hematology, University of Torino, Torino, Italy.

23. 24Department of Hematology, Centre Hospitalier Universitaire (CHU) de Liège, Liège, Belgium.

24. 28Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, Indiana.

25. 29Department of Hematology, Mayo Clinic, Rochester, Minnesota.

26. 30Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Abstract

Summary: The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Publisher

American Association for Cancer Research (AACR)

Subject

General Medicine

Link

https://aacrjournals.org/bloodcancerdiscov/article-pdf/doi/10.1158/2643-3230.BCD-21-0205/3162661/bcd-21-0205.pdf

Reference108 articles.

1. Defining and treating high-risk multiple myeloma;Usmani;Leukemia,2015

2. Toward personalized treatment in multiple myeloma based on molecular characteristics;Pawlyn;Blood,2019

3. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma;Weinhold;Blood,2016

4. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis;Walker;Leukemia,2019

5. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease;Mason;Leukemia,2020

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models;2024-01-11

2. A rational approach to functional high-risk myeloma;Hematology;2023-12-08

3. The role of staging in multiple myeloma;Expert Review of Hematology;2023-11-03

4. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11

5. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions;Blood Cancer Journal;2023-10-26